From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics

Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.